Wolfe Research downgraded Corcept Therapeutics (CORT) to Underperform from Peer Perform. Analysts established a $50.00 price target for the stock. This new target sits significantly below the recent trading price of $95.36.
Corcept shares have climbed 174% year-to-date. The stock surged following the March 2026 FDA approval of Lifyorli for platinum-resistant ovarian cancer.
Wolfe Research warns that the current valuation assumes a series of perfect outcomes. The stock price relies on a successful Cushing's syndrome NDA resubmission. Future growth also depends on favorable legal results for the company.